Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress

Core Insights - Amarin Corporation announced new subgroup data from the REDUCE-IT cardiovascular outcomes trial with VASCEPA/VAZKEPA, to be presented at the ESC Congress 2024 in London [1][2] Group 1: REDUCE-IT Trial Insights - The REDUCE-IT trial assessed the effect of icosapent ethyl (IPE) on cardiovascular events in patients with controlled LDL-C levels (41-100 mg/dL) and elevated triglycerides (135-499 mg/dL) [5] - The trial included 8,179 patients over seven years, focusing on those with established cardiovascular disease or diabetes and additional risk factors [5] - The median baseline triglyceride level was 216 mg/dL, indicating a significant population at risk [5] Group 2: Abstracts and Presentations - Accepted abstracts for the ESC Congress include analyses on the impact of baseline small dense low-density lipoprotein cholesterol on IPE's effects, and the association of triglycerides with cardiovascular events in acute coronary syndrome patients [2] - Presentations will cover various topics, including the prognosis of patients eligible for IPE treatment and the effects of EPA on lipoprotein(a) oxidation under high glucose conditions [3] Group 3: Company Commitment and Research Focus - Amarin is dedicated to investing in research that addresses residual cardiovascular risk beyond traditional lipid management, emphasizing the clinical utility of VASCEPA/VAZKEPA [4] - The company aims to enhance understanding of the mechanisms of action for IPE/EPA and the prevalence of residual cardiovascular risk associated with elevated triglyceride levels [4]